📚Is there a link between systemic inflammation and the progression of chronic kidney disease (CKD) or the occurrence of major adverse cardiovascular events (MACE – ischemic Stroke, myocardial infarction, heart failure, and atrial or ventricular fibrillation)?. 📚This week, we would like to highlight a study conducted by INI-CRCT members Jean-Michel Halimi and Valentin Maisons as well as Jean-Baptiste de Freminville, Arnaud Bisson, Stéphanie Chadet, and Laurent Fauchier, « ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation ».
📚This study compared the incidence of end-stage renal disease (ESRD) (i.e;, chronic dialysis or kidney transplantation), MACE, and mortality in CKD patients with high-sensitivity C-reactive protein (hsCRP) levels ≥ 2 mg/L versus those with levels <2 mg/L (using the TriNetX platform).
📚The results are based on 163,854 subjects with CKD (eGFR<60 mL/min/1.73 m2 or albumin-to-creatinine ratio > 200 mg/g) who had hsCRP measurements taken in the absence of infection.
📚Two groups were matched for CV risk factors (BP, LDL, initial treatment, GFR, and albuminuria): 27,580 subjects with hsCRP <2 mg/L. An hs CRP level ≥ 2 mg/L was associated with an increased risk of MACE, death and end-stage renal disease. Main message : Recognizing systemic inflammation as a factor associated with an increased risk of MACE and death in individuals with CKD (stage 3-4) or albuminuria (A3), and with an increased risk of end-stage renal disease in patients with diabetes mellitus, independently of traditional risk factors, is essential for improving their management.
